Compare Bristol-Myers Squibb Co (BMY) vs Marriott International Inc (MAR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Marriott International Inc — how do they compare? Bristol-Myers Squibb Co trades at $57 (market cap $116.30B), while Marriott International Inc trades at $362.11 (market cap $95.77B). The key difference: Bristol-Myers Squibb Co is the larger of the two by market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | MAR | |
|---|---|---|
Market Cap | $116.30B | $95.77B |
Sector | Health | Consumer Cyclical |
52-Week High | $62.37 | $402.54 |
52-Week Low | $42.60 | $255.35 |
Enterprise Value | $152.24B | $112.72B |
Dividend Yield | 4.42% | 0.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Marriott International (MAR) trades at $362.87, down 3.52% today, with a bearish technical signal and mixed earnings history. The company maintains strong revenue growth, reaching $26.19B in 2025, and a net income margin of 9.72%. Recent developments include the launch of Ask Bonvoy AI and expansion to 10,000 properties, though debt levels have risen to 58.83% of assets. Analyst consensus is a $387.33 price target with 44% buy ratings.
The outlook is cautiously optimistic given solid fundamentals and strategic initiatives, but high valuation ratios and increasing leverage pose risks. Near-term performance hinges on Q2 2026 earnings due August 3, 2026, with investor focus on debt management and travel demand sustainability amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Marriott International Inc
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →
